Is it appropriate to start Buspirone (Buspar) together with bupropion (Wellbutrin) in a patient who requires both anxiolytic and antidepressant therapy, and what dosing and monitoring should be used?

Combining Buspirone and Bupropion: A Practical Approach

Yes, starting buspirone (Buspar) together with bupropion (Wellbutrin) is appropriate and safe for patients requiring both anxiolytic and antidepressant therapy, with no significant drug-drug interactions or contraindications between these two medications.

Safety Profile of the Combination

The combination of buspirone and bupropion has a favorable safety profile with no documented pharmacokinetic interactions. Buspirone is metabolized primarily via CYP3A4, while bupropion is metabolized through CYP2B6, meaning they do not compete for the same metabolic pathways 1.

Critical safety consideration: The FDA label for buspirone specifically warns against combining it with MAOIs due to risk of elevated blood pressure and serotonin syndrome 1. However, bupropion is not an MAOI and does not pose this risk. The combination is well-tolerated in clinical practice 2, 3.

Clinical Evidence Supporting Combination Therapy

For Treatment-Resistant Depression

When patients fail to respond adequately to SSRI/SNRI monotherapy, augmentation with bupropion is superior to augmentation with buspirone for pure antidepressive effect 4. In the STAR*D trial, bupropion-SR showed superiority over buspirone on depression severity scales (P = 0.05) and resulted in fewer side effects (P = 0.03) 4.

However, augmentation with either bupropion or buspirone produces similar response and remission rates when added to citalopram (no significant difference in response or remission) 5, 6. The key difference is that bupropion reduces depression severity more effectively than buspirone 5.

For Comorbid Depression and Anxiety

• Buspirone effectively reduces anxiety symptoms in depressed patients already taking antidepressants, with HAMA scores decreasing from 25.2 to 15.4 over 12 weeks (p < 0.001), achieving a 39.1% response rate 7
• Bupropion can reduce anxiety in depressed patients despite concerns about its stimulating properties, showing comparable efficacy to SSRIs/SNRIs for mild-to-moderate anxiety 8
• The combination addresses both noradrenergic/dopaminergic (bupropion) and serotonergic (buspirone) pathways simultaneously

Dosing Algorithm

Starting Regimen

Bupropion:

• Start: 150 mg once daily in the morning
• After 3-4 days: Increase to 150 mg twice daily if tolerated
• Maximum: 300 mg/day (given as 150 mg twice daily) 9
• Critical timing: Give second dose before 3 PM to minimize insomnia 9

Buspirone:

• Start: 5 mg twice daily
• Titrate: Increase by 5 mg every 2-3 days as tolerated
• Target: 15-30 mg/day in divided doses (typically 7.5-15 mg twice daily)
• Maximum: 60 mg/day (20 mg three times daily) 9
• Important: Buspirone requires 2-4 weeks to become fully effective 9

When Starting Together

1. Initiate bupropion first at 150 mg daily for 3-7 days to assess tolerability
2. Add buspirone at 5 mg twice daily once bupropion is tolerated
3. Titrate bupropion to 150 mg twice daily by week 1-2
4. Titrate buspirone gradually to 15-30 mg/day over 2-4 weeks

Monitoring Requirements

First 4 Weeks (Critical Period)

• Behavioral activation/agitation: Monitor for restlessness, insomnia, impulsiveness, particularly in the first month 10
• Blood pressure and heart rate: Check at baseline, week 2, and week 4 due to bupropion's noradrenergic effects 11
• Anxiety symptoms: Assess weekly initially, as bupropion can provoke anxiety at higher doses 8
• Suicidality: Close monitoring especially in patients under 24 years old (FDA black box warning for all antidepressants) 10

Ongoing Monitoring

• Monthly assessment of depressive and anxiety symptoms
• Blood pressure checks every 3 months
• Reassess need for continuation after 9 months of stability 9

Absolute Contraindications

For Bupropion:

• Seizure disorders or conditions increasing seizure risk (brain metastases, stroke) 12, 9
• Current or recent (within 14 days) MAOI use 9
• Eating disorders (anorexia/bulimia) due to increased seizure risk
• Abrupt discontinuation of alcohol or benzodiazepines

For Buspirone:

• Current MAOI use or within 14 days of discontinuation 1
• Known hypersensitivity to buspirone

For the Combination:

• No additional contraindications specific to combining these medications

Special Populations and Considerations

Patients Requiring Opioid Therapy

Do not use this combination if the patient requires short-term or long-term opioid therapy. The naltrexone component in naltrexone-bupropion formulations blocks opioid receptors, but standard bupropion alone does not have this issue 11. However, buspirone has no opioid interactions 1.

Patients with Cardiovascular Disease

• Avoid bupropion in patients with uncontrolled hypertension 11
• Monitor blood pressure closely, especially in first 12 weeks
• Consider alternative if significant cardiovascular disease present

Patients Attempting Smoking Cessation

This combination may be particularly beneficial as bupropion is FDA-approved for smoking cessation 12. The combination of bupropion and naltrexone (not buspirone) has shown efficacy for smoking cessation with weight gain mitigation 11.

Common Pitfalls to Avoid

1. Starting bupropion at full dose: Always start at 150 mg daily to assess tolerability and reduce seizure risk
2. Dosing bupropion late in the day: Second dose after 3 PM significantly increases insomnia risk 9
3. Expecting immediate anxiolytic effect from buspirone: Counsel patients that buspirone requires 2-4 weeks for full effect 9
4. Combining with MAOIs: Absolute contraindication for both medications 9, 1
5. Ignoring CYP3A4 interactions with buspirone: Strong inhibitors (ketoconazole, itraconazole, nefazodone) can increase buspirone levels 13-50 fold, requiring dose reduction to 2.5 mg daily 1
6. Overlooking seizure risk factors: Carefully screen for history of seizures, head trauma, CNS tumors, or concurrent medications lowering seizure threshold

Efficacy Timeline

• Bupropion: Possible rapid improvement in energy within 1-2 weeks; full antidepressant effect by 4-6 weeks 9
• Buspirone: Anxiolytic effects emerge over 2-4 weeks; full effect by 4-6 weeks 9
• Combination: Assess response at 8-12 weeks before considering treatment failure

When to Discontinue

• If no improvement in depression after 8-12 weeks on adequate doses
• If intolerable side effects develop (discontinue offending agent)
• If seizure occurs (discontinue bupropion permanently)
• If serotonin syndrome develops (discontinue both immediately) 1

Discontinuation strategy: Taper both medications over 10-14 days to minimize withdrawal symptoms 9. Buspirone can be stopped more abruptly than bupropion if needed, as it has minimal discontinuation syndrome.